Seattle Genetics to acquire Cascadian Therapeutics for $614M to further bolster its cancer fight by Clare McGrane on January 31, 2018January 31, 2018 at 9:11 am Seattle Genetics, a biotechnology company that develops antibody-based cancer treatments, announced Wednesday that it will acquire Cascadian Therapeutics and the company’s small-molecule breast cancer treatment for about $614 million, or… Read More